Research
Cellular
After 12 weeks from baseline, serum ALT levels increased significantly to 83 (30-217) IU/L (P = 0.02).
Monitoring ALT levels is important as they may worsen after rifaximin treatment in NASH patients.
StrongSupportsmedium confidence
After 12 weeks from baseline, serum ALT increased to 83 (30-217) IU/L, P = 0.02.
Why this rating
Based on study design from abstract.
Source
Rifaximin in non‐alcoholic steatohepatitis: An open‐label pilot study
Jeremy Cobbold et al. · Hepatology Research · 2017
DOI 10.1111/hepr.12904
other · n=15Cited 49×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Rifaximin treatment for 6 weeks did not result in significant changes in alanine aminotransferase (ALT) levels in patients with NASH (55 [33-191] vs. 63 [41-218] IU/L, P = 0.41).Strong
- There was no significant change in hepatic insulin sensitivity after 6 weeks of rifaximin treatment (35.2 [15.3-51.7]% vs. 30.0 [10.8-50.5]%, P = 0.47).Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →